Does Lymph Node Dissection During Esophagectomy Impact the Long-Term Prognosis for Complete Responders After Neoadjuvant Therapy? A Meta-analysis.

Ann Surg OncolApr 27, 2026 (epub)
Clinical ResearchOncology (Medical)General Surgery

Xianbo Zhou, Donglai Chen, Peidong Song et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the impact of lymph node dissection (LND) on long-term survival in 2578 patients with pathologic complete response (pCR) after neoadjuvant therapy for esophageal cancer. The study found a significant association between adequate LND and improved overall survival (hazard ratio 0.70; 95% CI 0.58-0.84, p < 0.001), but no significant effect on disease-free survival.

Key findings

  • Adequate LND was associated with improved overall survival (hazard ratio 0.70; 95% CI 0.58-0.84, p < 0.001).
  • No significant survival advantage was observed for disease-free survival (hazard ratio 0.72; 95% CI 0.24-2.20, p = 0.568).
  • Extensive LND (over 40 nodes) did not provide additional survival benefits for overall survival.
  • Adequate LND correlated with superior overall survival in Western and adenocarcinoma populations.

Why it matters

Understanding the role of lymph node dissection in patients with pCR after neoadjuvant therapy is crucial for optimizing surgical strategies and improving patient outcomes in esophageal cancer.

Source

PubMed · PMID 42036602

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.